Tag: closed viral vector manufacturing platforms market trends

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Closed Viral Vector Manufacturing Platforms Market Size And Revenue Outlook Through 2030

The closed viral vector manufacturing platforms market size has seen rapid growth recently. It is forecast to expand from $1.96 billion in 2025 to $2.22 billion in 2026, at a compound annual growth rate (CAGR) of 13.4%. The expansion observed in prior periods can be attributed to an increase in gene therapy clinical trials, greater use of viral vectors in vaccine creation, the development of cell and gene therapy research initiatives, an increased regulatory emphasis on sterile production, and the early implementation of closed processing technologies.

The closed viral vector manufacturing platforms market is projected to experience substantial growth in the coming years. It is expected to reach $3.63 billion by 2030, progressing at a compound annual growth rate (CAGR) of 13.1%. This expansion during the forecast period can be attributed to the increasing commercialization of gene therapies, a rising demand for large-scale viral vector supply, growing investments in advanced biomanufacturing infrastructure, the expansion of contract manufacturing capacity, and an increasing focus on process standardization and automation. Significant trends anticipated during this period include the wider adoption of fully closed and automated production systems, a heightened demand for scalable viral vector manufacturing platforms, the increasing integration of single-use and modular components, the expansion of end-to-end closed processing workflows, and an enhanced focus on regulatory compliance and contamination control.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=36451196&type=smp&name=Closed%20Viral%20Vector%20Manufacturing%20Platforms%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Closed Viral Vector Manufacturing Platforms Market Growth Backed By Core Demand Fundamentals

The increasing number of clinical trials is anticipated to drive the expansion of the closed viral vector manufacturing platforms market in the future. Clinical trials are meticulously planned human studies conducted to evaluate the safety, effectiveness, and proper application of new medical therapies or interventions. The demand for these trials is growing due to an escalating need for innovative therapies, as the rising prevalence of chronic and complex diseases necessitates the development and testing of new drugs and treatments to address unmet medical needs. Closed viral vector manufacturing platforms support clinical trials by ensuring the consistent and sterile production of viral vectors, thereby guaranteeing the safety and reliability of the therapies under investigation. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, the total number of industry-sponsored clinical trials launched in the UK increased from 411 in 2022 to 426 in 2023. Therefore, the expanding volume of clinical trials is fueling the growth of the closed viral vector manufacturing platforms market.

Closed Viral Vector Manufacturing Platforms Market Segment Analysis: What Are The Core Market Categories?

The closed viral vector manufacturing platforms market covered in this report is segmented –

1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Lentiviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Retroviral Vectors, Other Product Types

2) By Workflow: Upstream Processing, Downstream Processing, Fill-Finish

3) By Application: Gene Therapy, Vaccines, Cell Therapy, Other Applications

4) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Manufacturing Organizations, Other End Users

Subsegments:

1) By Plasmid Deoxyribonucleic Acid (DNA): Supercoiled DNA, Linearized DNA, Minicircle DNA

2) By Lentiviral Vectors: Integrating Lentiviral Vectors, Non-Integrating Lentiviral Vectors

3) By Adenoviral Vectors: Replication-Deficient Adenoviral Vectors, Replication-Competent Adenoviral Vectors

4) By Adeno-Associated Viral Vectors (AAV): Single-Stranded AAV (ssAAV), Self-Complementary AAV (scAAV)

5) By Retroviral Vectors: Gamma-Retroviral Vectors, Alpha-Retroviral Vectors

6) By Other Product Types: Herpes Simplex Virus (HSV) Vectors, Vaccinia Virus Vectors, Baculovirus Vectors

Closed Viral Vector Manufacturing Platforms Market Growth Trends Reshaping The Competitive Landscape

Major companies in the closed viral vector manufacturing platforms market are concentrating on developing advanced solutions, such as nitro controllers, to prevent nitrogen-induced stress or toxicity in cell cultures. These nitro controllers are devices or systems used to monitor and regulate nitrogen levels or reactive nitrogen species in bioprocesses, ensuring optimal conditions for cell growth and product formation. For instance, in May 2025, Univercells Technologies, a Belgium-based biotechnology company, introduced the scale-X nitro controller. It is a compact and economical system engineered for large-scale viral vector and vaccine production. This system is compatible with 200 m² and 600 m² scale-X nitro bioreactors, supporting both adherent and suspension cell cultures. The system enables efficient production of AAV, lentiviral vectors, exosomes, and oncolytic viruses. Additionally, it allows rapid scale-up, facilitating the transition from research and development to commercial manufacturing within eight months.

Closed Viral Vector Manufacturing Platforms Market Top Companies Driving Competitive Growth

Major companies operating in the closed viral vector manufacturing platforms market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Karma Biotechnologies, Cell and Gene Therapy Catapult, CoJourney, Applied Biological Laboratories Inc., CEVEC Pharmaceuticals, Genesail Biotech Co. Ltd.

View The Full Closed Viral Vector Manufacturing Platforms Market Report:

https://thebusinessresearchcompany.com/report/closed-viral-vector-manufacturing-platforms-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Closed Viral Vector Manufacturing Platforms Market Global Footprint: Which Region Leads The Market?

North America was the largest region in the Closed Viral Vector Manufacturing Platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the closed viral vector manufacturing platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Closed Viral Vector Manufacturing Platforms Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The market for closed viral vector manufacturing platforms recorded substantial growth during the historical period. Its value was projected to increase from $1.96 billion in 2025 to $2.22 billion in 2026, reflecting a compound annual growth rate of 13.4%. This expansion in the historic era is linked to factors such as the rising number of gene therapy clinical trials, the growing application of viral vectors in vaccine manufacturing, the broadening of research initiatives in cell and gene therapy, an intensifying regulatory emphasis on sterile production processes, and the initial uptake of closed processing technologies.

The closed viral vector manufacturing platforms market is projected to experience robust growth over the coming years, with its value anticipated to reach $3.63 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.1%. This upward trajectory during the forecast period is fueled by several key factors, including the growing commercialization of gene therapies, heightened demand for large-scale viral vector supply, increased investments in advanced biomanufacturing infrastructure, expanded contract manufacturing capacity, and a greater emphasis on process standardization and automation. Key trends shaping this period involve the widespread adoption of fully closed and automated production systems, a rising need for scalable manufacturing platforms, the integration of single-use and modular components, the expansion of end-to-end closed processing workflows, and a stronger focus on regulatory compliance along with contamination control.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28981&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Closed Viral Vector Manufacturing Platforms Market Demand Drivers: What Is Fueling Industry Growth?

The expansion of the closed viral vector manufacturing platforms market is anticipated to be fueled by the increasing number of clinical trials. These trials represent carefully structured studies involving human participants, designed to evaluate the safety, effectiveness, and appropriate application of new medical therapies or interventions. A rising demand for clinical trials exists due to the greater need for innovative treatments, as the growing occurrence of chronic and complex illnesses stimulates the creation and assessment of new drugs and therapies for unmet medical requirements. This demand is supported by closed viral vector manufacturing platforms, which ensure reliable and sterile production of viral vectors, thereby guaranteeing the safety and dependability of the therapies under examination. As an illustration, December 2024 data from the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade body, showed that industry-sponsored clinical trials launched in the United Kingdom increased from 411 in 2022 to 426 in 2023. Consequently, market growth for closed viral vector manufacturing platforms is being driven by this rise in clinical trials.

Closed Viral Vector Manufacturing Platforms Market Segments: Where Are The Largest Growth Opportunities?

The closed viral vector manufacturing platforms market covered in this report is segmented –

1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Lentiviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Retroviral Vectors, Other Product Types

2) By Workflow: Upstream Processing, Downstream Processing, Fill-Finish

3) By Application: Gene Therapy, Vaccines, Cell Therapy, Other Applications

4) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Manufacturing Organizations, Other End Users

Subsegments:

1) By Plasmid Deoxyribonucleic Acid (DNA): Supercoiled DNA, Linearized DNA, Minicircle DNA

2) By Lentiviral Vectors: Integrating Lentiviral Vectors, Non-Integrating Lentiviral Vectors

3) By Adenoviral Vectors: Replication-Deficient Adenoviral Vectors, Replication-Competent Adenoviral Vectors

4) By Adeno-Associated Viral Vectors (AAV): Single-Stranded AAV (ssAAV), Self-Complementary AAV (scAAV)

5) By Retroviral Vectors: Gamma-Retroviral Vectors, Alpha-Retroviral Vectors

6) By Other Product Types: Herpes Simplex Virus (HSV) Vectors, Vaccinia Virus Vectors, Baculovirus Vectors

Closed Viral Vector Manufacturing Platforms Market Innovation Trends: Which Developments Are Transforming The Industry?

Key players in the closed viral vector manufacturing platforms market are concentrating on creating advanced innovations, such as nitro controllers, aimed at preventing nitrogen-related stress or toxicity in cell cultures. These nitro controllers function as instruments or systems designed to track and manage nitrogen levels or reactive nitrogen species within bioprocesses, thereby maintaining ideal conditions for cell proliferation and product generation. In May 2025, Univercells Technologies, a biotechnology firm based in Belgium, unveiled the scale-X nitro controller, which is a compact and cost-efficient solution tailored for large-scale viral vector and vaccine production. This system is designed to work with 200 m² and 600 m² scale-X nitro bioreactors and accommodates both adherent and suspension cell cultures. It facilitates efficient production of AAV, lentiviral vectors, exosomes, and oncolytic viruses, while also enabling rapid scale-up, which supports the transition from research and development to commercial manufacturing in just eight months.

Closed Viral Vector Manufacturing Platforms Market Major Participants And Competitive Dynamics

Major companies operating in the closed viral vector manufacturing platforms market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Karma Biotechnologies, Cell and Gene Therapy Catapult, CoJourney, Applied Biological Laboratories Inc., CEVEC Pharmaceuticals, Genesail Biotech Co. Ltd.

Access The Complete Closed Viral Vector Manufacturing Platforms Market Report:

https://www.thebusinessresearchcompany.com/report/closed-viral-vector-manufacturing-platforms-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Closed Viral Vector Manufacturing Platforms Market Regional Outlook: Where Are The Largest Opportunities Located?

North America was the largest region in the Closed Viral Vector Manufacturing Platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the closed viral vector manufacturing platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Closed Viral Vector Manufacturing Platforms Market By 2030 Based On Its 2026 Value?

The market for closed viral vector manufacturing platforms has experienced significant expansion in recent times. This market is projected to expand from $1.96 billion in 2025 to $2.22 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 13.4%. Factors contributing to this historical growth include an increase in gene therapy clinical trials, the expanded application of viral vectors in vaccine creation, the broadening of cell and gene therapy research initiatives, an intensified regulatory emphasis on sterile production, and the initial integration of closed processing techniques.

The market for closed viral vector manufacturing platforms is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $3.63 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 13.1%. This expansion during the projection period stems from factors such as the heightened commercialization of gene therapies, an escalating need for extensive viral vector supplies, increasing capital allocation towards sophisticated biomanufacturing infrastructure, an enlargement of contract manufacturing capabilities, and a greater emphasis on streamlining and automating processes. Key developments expected in the forecast timeframe encompass a wider uptake of completely closed and automated production systems, an increasing requirement for adaptable viral vector manufacturing platforms, greater incorporation of disposable and modular elements, an extension of comprehensive closed processing workflows, and a heightened commitment to adhering to regulations and preventing contamination.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28981&type=smp

What Important Drivers Are Powering The Closed Viral Vector Manufacturing Platforms Market Growth?

An anticipated increase in clinical trials is set to fuel the expansion of the closed viral vector manufacturing platforms market in the future. These trials involve meticulously planned human studies aimed at evaluating the safety, efficacy, and proper application of novel medical treatments or interventions. The demand for such trials is escalating, driven by the increasing necessity for advanced therapies, with the rising incidence of chronic and intricate diseases spurring the creation and assessment of new drugs and treatments to fulfill currently unmet healthcare requirements. Closed viral vector manufacturing platforms play a crucial role in supporting clinical trials by ensuring the consistent and sterile production of viral vectors, thereby guaranteeing the safety and dependability of the therapies being studied. For example, data from December 2024, provided by the UK trade association, the Association of the British Pharmaceutical Industry (ABPI), indicated that the aggregate number of industry-sponsored clinical trials initiated in the UK grew from 411 in 2022 to 426 in 2023. Consequently, the expanding volume of clinical trials is a key factor propelling the growth of the closed viral vector manufacturing platforms market.

Which Segment Divisions Form The Structure Of The Closed Viral Vector Manufacturing Platforms Market?

The closed viral vector manufacturing platforms market covered in this report is segmented –

1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Lentiviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Retroviral Vectors, Other Product Types

2) By Workflow: Upstream Processing, Downstream Processing, Fill-Finish

3) By Application: Gene Therapy, Vaccines, Cell Therapy, Other Applications

4) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Manufacturing Organizations, Other End Users

Subsegments:

1) By Plasmid Deoxyribonucleic Acid (DNA): Supercoiled DNA, Linearized DNA, Minicircle DNA

2) By Lentiviral Vectors: Integrating Lentiviral Vectors, Non-Integrating Lentiviral Vectors

3) By Adenoviral Vectors: Replication-Deficient Adenoviral Vectors, Replication-Competent Adenoviral Vectors

4) By Adeno-Associated Viral Vectors (AAV): Single-Stranded AAV (ssAAV), Self-Complementary AAV (scAAV)

5) By Retroviral Vectors: Gamma-Retroviral Vectors, Alpha-Retroviral Vectors

6) By Other Product Types: Herpes Simplex Virus (HSV) Vectors, Vaccinia Virus Vectors, Baculovirus Vectors

What Trends Are Affecting The Closed Viral Vector Manufacturing Platforms Market Dynamics?

Leading companies in the closed viral vector manufacturing platforms market are concentrating on creating sophisticated solutions like nitro controllers to mitigate nitrogen-related stress or toxicity within cell cultures. These devices, known as nitro controllers, monitor and adjust nitrogen levels or reactive nitrogen species during bioprocesses, thereby guaranteeing ideal environments for cell proliferation and product generation. As an illustration, Univercells Technologies, a biotechnology firm based in Belgium, introduced the scale-X nitro controller in May 2025. This system is both compact and cost-effective, designed for extensive viral vector and vaccine manufacturing. It functions with 200 m² and 600 m² scale-X nitro bioreactors and accommodates both adherent and suspension cell cultures. The system facilitates the efficient production of AAV, lentiviral vectors, exosomes, and oncolytic viruses. Furthermore, it permits swift scale-up, streamlining the move from research and development to commercial production within eight months.

Which Firms Are Competing In The Closed Viral Vector Manufacturing Platforms Market?

Major companies operating in the closed viral vector manufacturing platforms market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Karma Biotechnologies, Cell and Gene Therapy Catapult, CoJourney, Applied Biological Laboratories Inc., CEVEC Pharmaceuticals, Genesail Biotech Co. Ltd.

Access The Complete Closed Viral Vector Manufacturing Platforms Market Report:

https://www.thebusinessresearchcompany.com/report/closed-viral-vector-manufacturing-platforms-global-market-report

Which Region Holds The Largest Share In The Closed Viral Vector Manufacturing Platforms Market?

North America was the largest region in the Closed Viral Vector Manufacturing Platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the closed viral vector manufacturing platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Closed Viral Vector Manufacturing Platforms Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=28981&type=smp

Browse Through More Reports Similar to the Global Closed Viral Vector Manufacturing Platforms Market 2026, By The Business Research Company

Viral Vector Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Viral And Non Viral Vector Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

Oral Expectorant Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Closed Viral Vector Manufacturing Platforms Market In 2026, And How Will Its Value Evolve By 2030?

The closed viral vector manufacturing platforms market has seen substantial growth over the past few years. It is anticipated to expand from $1.96 billion in 2025 to $2.22 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.4%. This historical growth can be attributed to factors such as an increase in gene therapy clinical trials, broader use of viral vectors in vaccine development, the expansion of cell and gene therapy research programs, a rising regulatory focus on sterile manufacturing, and the early adoption of closed processing technologies.

The closed viral vector manufacturing platforms market size is projected to experience significant expansion in the coming years. It is expected to reach $3.63 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.1%. This growth during the forecast period can be attributed to the increasing commercialization of gene therapies, a rising demand for large-scale viral vector supply, growing investments in advanced biomanufacturing infrastructure, the expansion of contract manufacturing capacity, and an increasing focus on process standardization and automation. Major trends anticipated in this period include the increasing adoption of fully closed and automated production systems, a rising demand for scalable viral vector manufacturing platforms, the growing integration of single-use and modular components, the expansion of end-to-end closed processing workflows, and an enhanced focus on regulatory compliance and contamination control.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28981&type=smp

Which Major Drivers Are Influencing The Expansion Of The Closed Viral Vector Manufacturing Platforms Market?

The rising volume of clinical trials is anticipated to propel the expansion of the closed viral vector manufacturing platforms market in the foreseeable future. Clinical trials are meticulously designed studies conducted in humans to evaluate the safety, efficacy, and appropriate application of new medical treatments or interventions. The increasing demand for clinical trials is driven by the growing requirement for innovative therapies, as the rising prevalence of chronic and complex diseases necessitates the development and testing of new drugs and treatments to address unmet medical needs. Closed viral vector manufacturing platforms facilitate clinical trials by ensuring the consistent, sterile production of viral vectors, which in turn guarantees the safety and reliability of the therapies being investigated. For instance, in December 2024, figures from the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, indicated that the overall number of industry-sponsored clinical trials launched in the UK increased from 411 in 2022 to 426 in 2023. Thus, the escalating number of clinical trials is a key factor driving the growth of the closed viral vector manufacturing platforms market.

Which Segment Classifications Are Used In The Closed Viral Vector Manufacturing Platforms Market Segment Analysis?

The closed viral vector manufacturing platforms market covered in this report is segmented –

1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Lentiviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Retroviral Vectors, Other Product Types

2) By Workflow: Upstream Processing, Downstream Processing, Fill-Finish

3) By Application: Gene Therapy, Vaccines, Cell Therapy, Other Applications

4) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Manufacturing Organizations, Other End Users

Subsegments:

1) By Plasmid Deoxyribonucleic Acid (DNA): Supercoiled DNA, Linearized DNA, Minicircle DNA

2) By Lentiviral Vectors: Integrating Lentiviral Vectors, Non-Integrating Lentiviral Vectors

3) By Adenoviral Vectors: Replication-Deficient Adenoviral Vectors, Replication-Competent Adenoviral Vectors

4) By Adeno-Associated Viral Vectors (AAV): Single-Stranded AAV (ssAAV), Self-Complementary AAV (scAAV)

5) By Retroviral Vectors: Gamma-Retroviral Vectors, Alpha-Retroviral Vectors

6) By Other Product Types: Herpes Simplex Virus (HSV) Vectors, Vaccinia Virus Vectors, Baculovirus Vectors

What Trends Are Transforming The Closed Viral Vector Manufacturing Platforms Market?

Key companies in the closed viral vector manufacturing platforms market are prioritizing the creation of advanced solutions, including nitro controllers, to avert nitrogen-induced stress or toxicity in cell cultures. These nitro controllers serve as devices or systems for monitoring and regulating nitrogen levels or reactive nitrogen species during bioprocesses, thereby securing optimal environments for cell proliferation and product synthesis. For example, in May 2025, Univercells Technologies, a biotechnology firm headquartered in Belgium, unveiled its scale-X nitro controller. This system is a compact and cost-effective solution specifically designed for the large-scale manufacturing of viral vectors and vaccines. It offers compatibility with 200 m² and 600 m² scale-X nitro bioreactors and accommodates both adherent and suspension cell cultures. The system facilitates the efficient generation of AAV, lentiviral vectors, exosomes, and oncolytic viruses. Furthermore, it permits rapid scale-up, aiding the progression from research and development to commercial manufacturing within an eight-month timeframe.

Which Firms Are Contributing To The Closed Viral Vector Manufacturing Platforms Market Ecosystem?

Major companies operating in the closed viral vector manufacturing platforms market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Karma Biotechnologies, Cell and Gene Therapy Catapult, CoJourney, Applied Biological Laboratories Inc., CEVEC Pharmaceuticals, Genesail Biotech Co. Ltd.

Get The Full Closed Viral Vector Manufacturing Platforms Market Report:

https://www.thebusinessresearchcompany.com/report/closed-viral-vector-manufacturing-platforms-global-market-report

Where Is The Closed Viral Vector Manufacturing Platforms Market Most Concentrated Geographically?

North America was the largest region in the Closed Viral Vector Manufacturing Platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the closed viral vector manufacturing platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Closed Viral Vector Manufacturing Platforms Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/closed-viral-vector-manufacturing-platforms-global-market-report

Browse Through More Reports Similar to the Global Closed Viral Vector Manufacturing Platforms Market 2026, By The Business Research Company

Viral Vector Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Viral And Non Viral Vector Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

Oral Expectorant Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Closed Viral Vector Manufacturing Platforms Market Over The Period 2026–2030?

The market size for closed viral vector manufacturing platforms has experienced rapid expansion in recent years. This market is projected to grow from $1.96 billion in 2025 to $2.22 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.4%. The historical growth can be attributed to an increase in gene therapy clinical trials, greater use of viral vectors in vaccine development, the expansion of cell and gene therapy research programs, a growing regulatory focus on sterile manufacturing, and the early adoption of closed processing technologies.

The market size for closed viral vector manufacturing platforms is set to experience rapid expansion over the next few years. It is projected to achieve $3.63 billion by 2030, growing at a compound annual growth rate (CAGR) of 13.1%. This growth during the forecast period is primarily driven by the increasing commercialization of gene therapies, a rising need for large-scale viral vector supply, growing investments in advanced biomanufacturing infrastructure, the expansion of contract manufacturing capacity, and an increased focus on process standardization and automation. Prominent trends throughout the forecast period include the increasing adoption of fully closed and automated production systems, a heightened demand for scalable viral vector manufacturing platforms, the growing integration of single-use and modular components, the expansion of end-to-end closed processing workflows, and an enhanced focus on regulatory compliance and contamination control.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28981&type=smp

Which Major Factors Are Driving The Expansion Of The Closed Viral Vector Manufacturing Platforms Market?

The expansion in the number of clinical trials is projected to fuel the advancement of the closed viral vector manufacturing platforms market in the foreseeable future. These trials are meticulously planned human studies conducted to evaluate the safety, efficacy, and correct application of novel medical treatments or procedures. The escalating demand for clinical trials stems from the increasing requirement for innovative therapies, with the rising incidence of chronic and intricate diseases spurring the creation and assessment of new pharmaceuticals and treatments to meet currently unaddressed medical needs. Closed viral vector manufacturing platforms facilitate clinical trials by ensuring a uniform and sterile production of viral vectors, thereby guaranteeing the safety and dependability of the therapeutic interventions being studied. A notable example is provided by the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, which reported in December 2024 that the overall volume of industry-funded clinical trials initiated in the UK increased from 411 in 2022 to 426 in 2023. Consequently, the increasing volume of clinical trials is a primary impetus for the expansion of the closed viral vector manufacturing platforms market.

How Is The Closed Viral Vector Manufacturing Platforms Market Divided Into Its Major Segments?

The closed viral vector manufacturing platforms market covered in this report is segmented –

1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Lentiviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Retroviral Vectors, Other Product Types

2) By Workflow: Upstream Processing, Downstream Processing, Fill-Finish

3) By Application: Gene Therapy, Vaccines, Cell Therapy, Other Applications

4) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Manufacturing Organizations, Other End Users

Subsegments:

1) By Plasmid Deoxyribonucleic Acid (DNA): Supercoiled DNA, Linearized DNA, Minicircle DNA

2) By Lentiviral Vectors: Integrating Lentiviral Vectors, Non-Integrating Lentiviral Vectors

3) By Adenoviral Vectors: Replication-Deficient Adenoviral Vectors, Replication-Competent Adenoviral Vectors

4) By Adeno-Associated Viral Vectors (AAV): Single-Stranded AAV (ssAAV), Self-Complementary AAV (scAAV)

5) By Retroviral Vectors: Gamma-Retroviral Vectors, Alpha-Retroviral Vectors

6) By Other Product Types: Herpes Simplex Virus (HSV) Vectors, Vaccinia Virus Vectors, Baculovirus Vectors

How Are Trends Transforming The Closed Viral Vector Manufacturing Platforms Market Landscape?

Major companies within the closed viral vector manufacturing platforms market are concentrating on developing advanced solutions, such as nitro controllers, to mitigate nitrogen-induced stress or toxicity in cell cultures. Nitro controllers function as devices or systems for monitoring and regulating nitrogen levels or reactive nitrogen species in bioprocesses, thereby ensuring optimal conditions for cell growth and product formation. As an illustration, in May 2025, Univercells Technologies, a biotechnology company from Belgium, launched the scale-X nitro controller. This system is compact and economical, engineered for large-scale viral vector and vaccine production. It is compatible with 200 m² and 600 m² scale-X nitro bioreactors and accommodates both adherent and suspension cell cultures. The system supports the efficient production of AAV, lentiviral vectors, exosomes, and oncolytic viruses. Additionally, it permits rapid scale-up, enabling the transition from research and development to commercial manufacturing in just eight months.

Who Are The Prominent Organizations Shaping The Closed Viral Vector Manufacturing Platforms Market?

Major companies operating in the closed viral vector manufacturing platforms market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Karma Biotechnologies, Cell and Gene Therapy Catapult, CoJourney, Applied Biological Laboratories Inc., CEVEC Pharmaceuticals, Genesail Biotech Co. Ltd.

Read the full closed viral vector manufacturing platforms market report here:

https://www.thebusinessresearchcompany.com/report/closed-viral-vector-manufacturing-platforms-global-market-report

Which Region Currently Holds The Largest Share Of The Closed Viral Vector Manufacturing Platforms Market?

North America was the largest region in the Closed Viral Vector Manufacturing Platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the closed viral vector manufacturing platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Closed Viral Vector Manufacturing Platforms Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28981&type=smp

Browse Through More Reports Similar to the Global Closed Viral Vector Manufacturing Platforms Market 2026, By The Business Research Company

Viral Vector Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Viral And Non Viral Vector Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

Oral Expectorant Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the closed viral vector manufacturing platforms market from 2026–2035 with trusted insights from The Business Research Company

How is the Closed Viral Vector Manufacturing Platforms Market size predicted to change over the forecast window of 2026–2035?

The market size for closed viral vector manufacturing platforms has experienced rapid growth in recent years. This market is expected to expand from $1.96 billion in 2025 to $2.22 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.4%. Historically, this growth can be ascribed to a surge in gene therapy clinical trials, the increased deployment of viral vectors in vaccine development, the broadening of cell and gene therapy research programs, a heightened regulatory focus on sterile manufacturing, and the early adoption of closed processing technologies.

The closed viral vector manufacturing platforms market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach $3.63 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.1%. Factors contributing to this growth during the forecast timeframe include the accelerating commercialization of gene therapies, an escalating need for extensive viral vector supplies, increasing capital expenditure in cutting-edge biomanufacturing facilities, the broadening of contract manufacturing capabilities, and a heightened emphasis on standardizing and automating processes. Key trends expected over the forecast period encompass a greater uptake of entirely closed and automated production systems, a surging requirement for scalable viral vector manufacturing platforms, the wider incorporation of single-use and modular parts, the broadening of complete closed processing workflows, and an intensified focus on adherence to regulations and managing contamination.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28981&type=smp

Which Drivers Are Contributing To The Expansion Of The Closed Viral Vector Manufacturing Platforms Market?

An increasing volume of clinical trials is anticipated to drive expansion in the closed viral vector manufacturing platforms market moving ahead. These trials involve meticulously planned human studies aimed at evaluating the safety, efficacy, and suitability of novel medical treatments or procedures. The escalating need for inventive therapies fuels the demand for clinical trials, as the rising incidence of chronic and intricate diseases necessitates the creation and evaluation of new drugs and treatments to meet currently unaddressed medical requirements. Closed viral vector manufacturing platforms facilitate clinical trials through the reliable and aseptic production of viral vectors, thereby guaranteeing the safety and dependability of the therapeutic agents being studied. As an illustration, data from December 2024, provided by the Association of the British Pharmaceutical Industry (ABPI), a trade association based in the UK, indicated that the aggregate count of industry-funded clinical trials initiated in the UK climbed from 411 in 2022 to 426 in 2023. Consequently, the increasing volume of clinical trials is a key impetus for the expansion of the closed viral vector manufacturing platforms market.

What Segment Categories Are Covered In The Closed Viral Vector Manufacturing Platforms Market?

The closed viral vector manufacturing platforms market covered in this report is segmented –

1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA), Lentiviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Retroviral Vectors, Other Product Types

2) By Workflow: Upstream Processing, Downstream Processing, Fill-Finish

3) By Application: Gene Therapy, Vaccines, Cell Therapy, Other Applications

4) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Manufacturing Organizations, Other End Users

Subsegments:

1) By Plasmid Deoxyribonucleic Acid (DNA): Supercoiled DNA, Linearized DNA, Minicircle DNA

2) By Lentiviral Vectors: Integrating Lentiviral Vectors, Non-Integrating Lentiviral Vectors

3) By Adenoviral Vectors: Replication-Deficient Adenoviral Vectors, Replication-Competent Adenoviral Vectors

4) By Adeno-Associated Viral Vectors (AAV): Single-Stranded AAV (ssAAV), Self-Complementary AAV (scAAV)

5) By Retroviral Vectors: Gamma-Retroviral Vectors, Alpha-Retroviral Vectors

6) By Other Product Types: Herpes Simplex Virus (HSV) Vectors, Vaccinia Virus Vectors, Baculovirus Vectors

Which Trends Are Shaping Activity Within The Closed Viral Vector Manufacturing Platforms Market?

Leading firms within the closed viral vector manufacturing platforms market are concentrating on creating sophisticated solutions, like nitro controllers, aimed at averting nitrogen-induced stress or toxicity in cell cultures. These nitro controllers function as devices or systems designed to monitor and regulate nitrogen levels or reactive nitrogen species during bioprocesses, thereby ensuring ideal conditions for cell growth and product generation. An example of this is Univercells Technologies, a biotechnology company from Belgium, which introduced the scale-X nitro controller in May 2025. This system is both compact and cost-effective, engineered specifically for large-scale production of viral vectors and vaccines. It offers compatibility with 200 m² and 600 m² scale-X nitro bioreactors and can accommodate both adherent and suspension cell cultures. The system facilitates the efficient production of AAV, lentiviral vectors, exosomes, and oncolytic viruses. Furthermore, it permits swift scale-up, streamlining the progression from research and development phases to commercial manufacturing within an eight-month timeframe.

Which Leading Companies Dominate The Closed Viral Vector Manufacturing Platforms Market Share?

Major companies operating in the closed viral vector manufacturing platforms market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Karma Biotechnologies, Cell and Gene Therapy Catapult, CoJourney, Applied Biological Laboratories Inc., CEVEC Pharmaceuticals, Genesail Biotech Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/closed-viral-vector-manufacturing-platforms-global-market-report

How Does The Closed Viral Vector Manufacturing Platforms Market Perform Across Major Global Regions?

North America was the largest region in the Closed Viral Vector Manufacturing Platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the closed viral vector manufacturing platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Closed Viral Vector Manufacturing Platforms Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28981&type=smp

Browse Through More Reports Similar to the Global Closed Viral Vector Manufacturing Platforms Market 2026, By The Business Research Company

Viral Vector Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Viral And Non Viral Vector Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

Oral Expectorant Market Report 2026

https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model